Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
株価
$0.28545656
時価総額
$4.50M
変化(1日)
5.97%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)のEPS
June 2024 時点のEPS TTM: $-1.95
Acticor Biotech SASの最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-1.95です。2022年末には、EPSは$-1.62で、2021年のEPS$-1.84と減少でした。
Acticor Biotech SASのEPS履歴(2010から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$3.62 -285.38%
DK
$15.47 -891.71%
US
$43.12 -2,306.76%
US
$9.62 -592.36%
BE
$2.98 -252.51%
AU